Morgan Stanley Rates Certara (CERT) Stock and Growth Potential

Certara, Inc. (NASDAQ:CERT) is highlighted as one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds by Morgan Stanley, with an “Equal Weight” rating and $16 price objective. The company’s strategic review of its regulatory services business and potential opportunities related to FDA’s new approach methodologies are monitored.

Certara, Inc. (NASDAQ:CERT) reaffirms FY 2025 guidance, expecting revenue between $415 million – $425 million and adjusted EBITDA margin of 30-32%. Q1 2025 total revenue reached $106.0 million, a 10% YoY growth on reported and constant currency basis, including $5.9 million of Chemaxon revenue.

Certara, Inc. (NASDAQ:CERT) saw revenue growth in Q1 2025 due to biosimulation software portfolio and M&A contribution. Total bookings amounted to $118.2 million, a 12% YoY growth on a reported basis, with $4.9 million of Chemaxon bookings included.

While CERT shows investment potential, other AI stocks may offer greater upside and less downside risk. For those seeking undervalued AI stocks benefiting from current trends, explore the best short-term AI stock in a free report.

For more insights on AI stocks and growth opportunities, check out 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now. This article is originally published at Insider Monkey.

Read more at Yahoo Finance: Morgan Stanley Assumes Coverage of Certara (CERT) Stock